Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Illumina Launches TruGenome Undiagnosed Disease Test

Published: Monday, October 28, 2013
Last Updated: Monday, October 28, 2013
Bookmark and Share
A single clinical test provides unbiased analysis of the whole genome for challenging cases.

Illumina, Inc. has announced the launch of its TruGenome Undiagnosed Disease Test provided by the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory (ICSL).

This new service uses whole human genome sequencing to assist physicians in identifying the underlying genetic cause of a rare or undiagnosed disease.

By providing physicians with more comprehensive information from a single test, the service enables a broader understanding of the genetic basis for disease.

The ICSL uses proven Illumina next-generation sequencing technology to provide a complete picture of the genome.

Illumina's team of Ph.D. geneticists and certified medical geneticists with expertise in reviewing whole-genome data as it pertains to genetic disease performs the analysis using Illumina's VariantStudio software for rigorous variant classification.

VariantStudio aggregates data from multiple sources into a single database that is updated as new discoveries are made, ensuring that analysis is based on current knowledge of clinically relevant gene variants.

"Whole-genome sequencing and interpretation tools have the potential to benefit the 350 million people worldwide affected by rare diseases, 50 percent of whom are children. By offering the TruGenome Undiagnosed Disease Test, and partnering with other leading medical institutions that are beginning to offer whole-genome sequencing tests for the diagnosis of rare diseases, Illumina intends to demonstrate the clinical utility of whole-genome sequencing in these cases," said Matt Posard, Senior Vice President and General Manager of Illumina's Translational and Consumer Genomics business.

Posard continued, "By developing and defining the tools needed to perform whole-genome sequencing and interpret the results in rare disease cases, we hope to enable clinical laboratories to offer these services worldwide in the future. In the end, we all want to see answers for patients and families facing an undiagnosed disease."

"Whole-genome sequencing is proving to be an invaluable tool in the identification of rare and undiagnosed disease, and as we learn more about the human genome and its impact on human health, I expect sequencing to become a regular component of health care. Medical College of Wisconsin's partnership with Illumina for clinical testing services has greatly advanced our capacity in this area," said Howard Jacob, Director of the Human and Molecular Genetics Center and Warren P. Knowles Chair of Genetics at the Medical College of Wisconsin.

The new TruGenome Undiagnosed Disease Test will be available for physicians to order beginning in December 2013.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Burning Rock and Illumina Collaborate on Molecular Diagnostics for Oncology
Collaboration highlights the ever-increasing importance of genomics to improve healthcare in China.
Tuesday, August 25, 2015
Illumina, Warburg Pincus, and Sutter Hill Ventures Form Helix
LabCorp to be initial strategic partner in development of consumer applications.
Tuesday, August 18, 2015
Illumina Accelerator Invests in Second Class of Genomics Startups
Startups selected from Spain, Oregon, and California to advance breakthrough applications.
Thursday, August 06, 2015
Illumina to Acquire GenoLogics
Illumina has signed a definitive agreement to acquire GenoLogics, a developer of LIMS for life science organizations.
Wednesday, August 05, 2015
Illumina Names Sanjay Chikarmane as SVP and General Manager
Chikarmane will report to Illumina President, Francis deSouza.
Tuesday, July 21, 2015
Discordant NIPT Test Results May Reflect Presence of Maternal Cancer
Results published in Journal of the American Medical Association.
Tuesday, July 14, 2015
Biomed Realty and Illumina Announce New Build-to-Suit Laboratory Building
New building to be located in scientific research park, Granta Park, and will serve as Illumina’s new European headquarters.
Friday, June 26, 2015
Annoroad and Illumina to Co-Develop NGS Diagnostic System
Both Companies have entered into an agreement to jointly develop advanced clinical applications for reproductive health.
Thursday, June 11, 2015
Illumina, Merck KGaA and Genea Form the Global Fertility Alliance
Global fertility alliance will identify and work on improvements of fertility-related laboratory processes.
Tuesday, June 09, 2015
Illumina Files New Patent Infringement Suit
Company has filed a new suit against Ariosa Diagnostics, Inc. and Roche Molecular Systems, Inc.
Tuesday, May 19, 2015
The Agrigenomics Market
Exponential population growth and changing climate patterns are creating unique challenges for the agriculture industry. To continue to address global food needs, many researchers, breeders, and farms are turning to genomics, or DNA science, to optimize production.
Thursday, May 07, 2015
Berry Genomics NextSeq CN500 Instrument Receives CFDA Premarket Clearance
Products collaboratively developed by Berry Genomics and Illumina Serve Chinese clinical NIPT market.
Wednesday, April 01, 2015
Illumina Accelerator Secures $40 Million Boost Capital to Back New Graduates
Obtains commitment from viking global investors to advance genomics startups.
Friday, February 27, 2015
Lockheed Martin and Illumina to Collaborate
New strategic alliance to collaborate on developing genomics solutions to improve public health and wellness.
Tuesday, January 13, 2015
£15m Initiative Puts Scotland at Forefront of Gene-Led Healthcare
Initiative sees the Universities of Edinburgh and Glasgow partner with Illumina.
Monday, January 12, 2015
Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Searching Big Data Faster
Theoretical analysis could expand applications of accelerated searching in biology, other fields.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
How DNA ‘Proofreader’ Proteins Pick and Edit Their Reading Material
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have discovered how two important proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!